Empiric therapy-10-day concomitant, bismuth quadruple or 14-day triple therapy: none is best.
作者信息
Yamaoka Yoshio, Graham David Y
机构信息
Department of Medicine, Michael E. DeBakey VA Medical Center and Baylor College of Medicine, Houston, Texas, USA.
Department of Environmental and Preventive Medicine, Oita University Faculty of Medicine, Yufu, Japan.
出版信息
Transl Cancer Res. 2016 Dec;5(Suppl 7):S1476-S1478. doi: 10.21037/tcr.2016.12.39.
Abstract
摘要
相似文献
1
Empiric therapy-10-day concomitant, bismuth quadruple or 14-day triple therapy: none is best.经验性治疗——10天联合铋剂四联疗法或14天三联疗法：没有一种是最佳的。
Transl Cancer Res. 2016 Dec;5(Suppl 7):S1476-S1478. doi: 10.21037/tcr.2016.12.39.
2
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.一线治疗幽门螺杆菌感染中含铋四联、14 天三联疗法的比较：一项多中心、开放标签、随机试验。
Lancet. 2016 Nov 12;388(10058):2355-2365. doi: 10.1016/S0140-6736(16)31409-X. Epub 2016 Oct 18.
3
[The efficacy and safety of quadruple therapy without bismuth (concomitant therapy) in the treatment of patients with Helicobacter pylori - associated gastric and duodenal peptic ulcer disease].无铋四联疗法（联合疗法）治疗幽门螺杆菌相关性胃及十二指肠消化性溃疡疾病患者的疗效和安全性
Ter Arkh. 2019 Aug 15;91(8):28-33. doi: 10.26442/00403660.2019.08.000382.
4
Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial.质子泵抑制剂、铋剂、四环素和左氧氟沙星组成的十日四联疗法在幽门螺杆菌感染二线治疗中比标准左氧氟沙星三联疗法更有效：一项随机对照试验
Am J Gastroenterol. 2017 Sep;112(9):1374-1381. doi: 10.1038/ajg.2017.195. Epub 2017 Jul 18.
5
Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments.在标准三联疗法或不含铋剂的四联疗法失败后，采用含左氧氟沙星和铋剂的四联疗法进行幽门螺杆菌二线挽救治疗。
Aliment Pharmacol Ther. 2015 Apr;41(8):768-75. doi: 10.1111/apt.13128. Epub 2015 Feb 23.
6
[Cuadruple concomitant non-bismuth therapy vs. classical triple therapy as first line therapy for Helicobacter pylori infection].[四联同步非铋剂疗法与经典三联疗法作为幽门螺杆菌感染一线治疗的比较]
Med Clin (Barc). 2016 Sep 2;147(5):199-201. doi: 10.1016/j.medcli.2016.05.017. Epub 2016 Jun 30.
7
Comparison of four different regimens against Helicobacter pylori as a first-line treatment: A prospective, cross-sectional, comparative, open trial in Chinese children.四种不同方案作为一线治疗方案根除幽门螺杆菌的比较：中国儿童的前瞻性、横断面、对照、开放试验。
Helicobacter. 2020 Apr;25(2):e12679. doi: 10.1111/hel.12679. Epub 2020 Jan 20.
8
Second-line rescue treatment of infection: Where are we now?二线解救治疗 感染：我们现在在哪里？
World J Gastroenterol. 2018 Oct 28;24(40):4548-4553. doi: 10.3748/wjg.v24.i40.4548.
9
Ten-day bismuth-containing quadruple therapy is effective as first-line therapy for Helicobacter pylori-related chronic gastritis: a prospective randomized study in China.10 天铋剂四联疗法作为一线治疗方案用于治疗幽门螺杆菌相关慢性胃炎的有效性：中国的一项前瞻性随机研究。
Clin Microbiol Infect. 2017 Jun;23(6):391-395. doi: 10.1016/j.cmi.2016.12.032. Epub 2017 Jan 7.
10
Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.经验性四联与三联疗法治疗幽门螺杆菌感染的初步治疗：疗效和耐受性的系统评价和荟萃分析。
Am J Gastroenterol. 2010 Jan;105(1):65-73. doi: 10.1038/ajg.2009.508. Epub 2009 Sep 15.
引用本文的文献
1
A Bioluminescence-Based Drug Screen Identifies Activities of Fexinidazole and Its Metabolites against .基于生物发光的药物筛选确定了非昔硝唑及其代谢物对……的活性 。 （原文结尾不完整，翻译可能存在一定局限性）
Antibiotics (Basel). 2022 Nov 11;11(11):1605. doi: 10.3390/antibiotics11111605.
本文引用的文献
1
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.一线治疗幽门螺杆菌感染中含铋四联、14 天三联疗法的比较：一项多中心、开放标签、随机试验。
Lancet. 2016 Nov 12;388(10058):2355-2365. doi: 10.1016/S0140-6736(16)31409-X. Epub 2016 Oct 18.
2
Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report.幽门螺杆菌感染的管理——马斯特里赫特 V/佛罗伦萨共识报告。
Gut. 2017 Jan;66(1):6-30. doi: 10.1136/gutjnl-2016-312288. Epub 2016 Oct 5.
3
Helicobacter pylori therapy: a paradigm shift.幽门螺杆菌治疗：范式转变。
Expert Rev Anti Infect Ther. 2016 Jun;14(6):577-85. doi: 10.1080/14787210.2016.1178065. Epub 2016 May 3.
4
Role of bismuth in improving Helicobacter pylori eradication with triple therapy.铋在三联疗法提高幽门螺杆菌根除率中的作用。
Gut. 2016 May;65(5):870-8. doi: 10.1136/gutjnl-2015-311019. Epub 2016 Feb 4.
5
Azithromycin versus Doxycycline for Urogenital Chlamydia trachomatis Infection.阿奇霉素与多西环素治疗泌尿生殖系统沙眼衣原体感染的比较
N Engl J Med. 2015 Dec 24;373(26):2512-21. doi: 10.1056/NEJMoa1502599.
6
Hp-normogram (normo-graham) for Assessing the Outcome of H. pylori Therapy: Effect of Resistance, Duration, and CYP2C19 Genotype.用于评估幽门螺杆菌治疗结果的Hp正态概率图（正态-格雷厄姆图）：耐药性、疗程和CYP2C19基因型的影响
Helicobacter. 2016 Apr;21(2):85-90. doi: 10.1111/hel.12287. Epub 2015 Nov 27.
7
Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy.铋剂、兰索拉唑、阿莫西林和甲硝唑或克拉霉素作为一线幽门螺杆菌治疗。
Gut. 2015 Nov;64(11):1715-20. doi: 10.1136/gutjnl-2015-309900. Epub 2015 Sep 2.
8
How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly.如何有效使用铋剂四联疗法：优点、缺点与问题
Gastroenterol Clin North Am. 2015 Sep;44(3):537-63. doi: 10.1016/j.gtc.2015.05.003. Epub 2015 Jun 19.
9
Kyoto global consensus report on Helicobacter pylori gastritis.《京都幽门螺杆菌胃炎全球共识报告》
Gut. 2015 Sep;64(9):1353-67. doi: 10.1136/gutjnl-2015-309252. Epub 2015 Jul 17.
10
Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits.幽门螺杆菌最新进展：胃癌、可靠的治疗方法及潜在益处
Gastroenterology. 2015 Apr;148(4):719-31.e3. doi: 10.1053/j.gastro.2015.01.040. Epub 2015 Feb 2.
Zotero 插件